Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease

• Главные авторы: Diane E. Milenic (Автор), Paul S. Albert (Автор), Martin W. Brechbiel (Автор), Lanea M. M. Keller (Автор), Kwamena E. Baidoo (Автор), Geoffrey L. Ray (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2011-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Studies from this laboratory have demonstrated the potential of targeting HER2 for therapeutic and imaging applications with medically relevant radionuclides. To expand the repertoire of trastuzumab as a radioimmunoconjugate (RIC) vector, use of 177Lu was investigated. The combination of a 6.7 d hal...